USRM (US Stem Cell) Ending Cash Position: $0.01 Mil (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

USRM US Stem Cell Inc USRM
12 GF Score
Price $0.00
View Full Analysis

What is US Stem Cell Ending Cash Position?

US Stem Cell USRM 12 Ending Cash Position is $0.01 Mil as of Dec. 2022. GuruFocus rates USRM with a GF Score™ of 12/100.

US Stem Cell's Ending Cash Position for the quarter that ended in Dec. 2022 was $0.01 Mil.

US Stem Cell's quarterly Ending Cash Position increased from Jun. 2022 ($0.01 Mil) to Sep. 2022 ($0.03 Mil) but then declined from Sep. 2022 ($0.03 Mil) to Dec. 2022 ($0.01 Mil).

US Stem Cell's annual Ending Cash Position increased from Dec. 2020 ($0.02 Mil) to Dec. 2021 ($0.04 Mil) but then declined from Dec. 2021 ($0.04 Mil) to Dec. 2022 ($0.01 Mil).

US Stem Cell Ending Cash Position Related Terms

US Stem Cell Ending Cash Position Historical Data

* Premium members only.

The historical data trend for US Stem Cell's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

US Stem Cell Ending Cash Position Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.36 0.00 0.02 0.04 0.01

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.01 0.01 0.03 0.01
USRM
12GF Score
US Stem Cell Inc USRM
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

US Stem Cell Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

US Stem Cell's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.039+-0.034
=0.00

US Stem Cell's Ending Cash Position for the quarter that ended in Dec. 2022 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.03+-0.025
=0.01

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.01 Mil mean?
US Stem Cell (USRM) has a Ending Cash Position of $0.01 Mil as of Dec. 2022. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on US Stem Cell and its competitors.
Is US Stem Cell's Ending Cash Position too high?
US Stem Cell's current Ending Cash Position is $0.01 Mil. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's Ending Cash Position compare to NOVNQ and RGRX?
US Stem Cell's Ending Cash Position of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on US Stem Cell and its competitors. US Stem Cell's current Ending Cash Position is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current Ending Cash Position of $0.01 Mil. The current Ending Cash Position is $0.01 Mil. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For US Stem Cell (USRM), the current Ending Cash Position is $0.01 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

US Stem Cell Business Description

Address 1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score

Get the complete analysis for USRM

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price